---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-005467"
form_type: "8-K"
ticker: "VSBC"
cik: "0001697884"
company_name: "VITASPRING BIOMEDICAL CO. LTD."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:44:43.569120+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEO and Chairman of VitaSpring face multiple Taiwan legal proceedings including indictments

## Summary
- CEO Kao and Chairman Chu involved in criminal civil cases for unauthorized IP use, violations of Taiwan's Pharmaceutical Affairs Act.
- Chu and Kao indicted March 31 2025 under Pharmaceutical Affairs Act; court hearings June 2 2025, next set for Sept 22 2025.
- TMU fiduciary duty case ongoing; NT$500M (approx $15.5M) civil damages claim against Chu and others.
- In exosome case, Chu acquitted by Tainan District Court; prosecutor has appealed.
- Company says it is not a named party and does not expect material adverse effect on operations.

## SEC filing metadata
- accession: 0001683168-25-005467
- form_type: 8-K
- ticker: VSBC
- cik: 0001697884
- company_name: VITASPRING BIOMEDICAL CO. LTD.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1697884/000168316825005467/0001683168-25-005467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1697884/000168316825005467/vitaspring_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-005467
- JSON: https://secwatch.observer/filing/0001683168-25-005467.json
- Plain text: https://secwatch.observer/filing/0001683168-25-005467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.